查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854614

血糖監測市場按應用、最終用戶、產品類型和分銷管道分類－2025-2032年全球預測

Blood Glucose Monitoring Market by Application, End User, Product Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血糖監測市場規模將達到 272.3 億美元，複合年成長率為 8.59%。

關鍵市場統計數據
基準年 2024 140.8億美元
預計年份：2025年 152.7億美元
預測年份 2032 272.3億美元
複合年成長率 (%) 8.59%

本書全面而深刻地概述了技術進步、不斷演變的護理模式和監管力量如何改變血糖值監測實踐和患者預後。

血糖值管理融合了臨床療效、患者自主性和技術創新。過去十年，感測器精度、數據連接性和穿戴式設備人體工學的不斷提升，使血糖監測從零散的測量轉變為持續的、以洞察為導向的護理。因此，臨床醫生擴大將基於趨勢的資訊融入治療決策，而患者則受益於即時回饋，從而更好地進行自我管理和提高治療依從性。這種轉變影響著初級保健、門診和專科護理的產品開發、報銷策略和診療路徑。

同時，監管力度和品質標準不斷加強，迫使製造商和服務供應商優先考慮互通性、資料隱私和臨床檢驗。醫療保健系統正在調整報銷框架，以認可能夠實現遠端監測和遠端醫療的干涉措施，從而進一步推動先進監測技術的應用。此外，人口結構和生活方式因素持續推動對妊娠糖尿病管理、小兒科護理和成人慢性病管理解決方案的需求。綜上所述，這些發展為尋求透過改善血糖控制結果來創造價值的相關人員創造了一個更複雜但也充滿機會的環境。

本執行摘要綜合了這些動態，揭示了變革性的結構轉變，並為臨床領導者、產品團隊、支付方和分銷合作夥伴在應對不斷變化的血糖值監測領域時提出了可操作的建議。

感測器技術的進步、數位化整合和分散式醫療模式如何融合，從而變革血糖監測和臨床工作流程

由於技術融合、醫療服務模式的演變以及患者期望的改變，血糖監測領域正在經歷顯著變化。首先，感測器技術的成熟使其能夠支援更長的佩戴時間、在整個血糖值範圍內提高測量精度並降低校準要求。因此，臨床醫生可以長期獲得更穩定的數據，從而更好地識別血糖模式並儘早進行干預。同時，數位健康基礎設施（包括雲端平台、可互通的電子健康記錄和安全的患者門戶網站）的擴展，使得血糖數據能夠無縫地傳輸臨床工作流程，縮短了從測量到臨床干預的週期。

此外，醫療服務模式正朝著去中心化方向發展。遠端監測、虛擬糖尿病教育和社區計畫正在減少對集中式實驗室檢測的依賴，並促進在門診和居家照護中早期療育。這些醫療服務創新與提升病患參與度的改善措施相輔相成，例如簡化的設備介面、個人化提醒和遊戲化的依從性工具。同時，支付方和監管機構正在調整政策，以支持遠端監測和真實世界證據的生成，從而進一步加速這些技術的普及應用。

綜上所述，這些轉變形成了一個回饋循環：更優質的數據帶來更優質的醫療服務，而更完善的醫療模式又推動了對先進監測解決方案的需求。能夠協調產品開發、報銷策略和臨床整合的相關人員，最能掌握價值，並推動血糖控制的持續改善。

2025 年關稅變化如何影響血糖監測解決方案的製造和分銷的採購、供應彈性和定價策略

關稅政策和貿易動態將對醫療設備供應鏈、零件採購和定價策略產生重大影響。以血糖值監測領域為例，2025年關稅的累積變化迫使製造商和經銷商重新評估其採購路徑，實現供應商多元化，並最佳化庫存策略以降低成本波動風險。企業採取的應對措施包括加快近岸外包和區域採購舉措，以減少跨境關稅波動帶來的風險，並增強供應鏈的韌性。因此，採購團隊調整了合約結構，納入了感測器、黏合劑和電子模組等關鍵零件的替代供應商。

營運調整並未止步於採購環節。物流團隊實施了多式聯運方案，並增加了區域配送中心的緩衝庫存，以確保供應的連續性。這些措施保障了醫院、居家照護機構和零售通路的產品供應，同時避免了終端用戶面臨價格的突然波動。同時，製造商加強了與委託製造和零件供應商的談判，以分擔風險並穩定單位經濟效益。

從策略角度來看，關稅帶來的壓力促使商業部門和監管部門加強合作，以簡化清關和合規流程。這也凸顯了產品設計決策的重要性，即減少對關稅敏感型原料的依賴。最終，那些採用敏捷採購、投資區域供應節點並將定價框架與成本轉嫁機制結合的企業，能夠更有效地應對關稅環境，同時在臨床和消費管道中維持服務水準。

精準的細分洞察揭示了臨床應用案例、終端用戶需求、產品系列和通路，從而指導有針對性的策略和創新。

細分市場分析明確了臨床需求、支付方關注點和產品創新之間的交匯點，從而能夠針對治療和商業層面製定精準策略。基於應用領域，市場分析涵蓋妊娠期糖尿病、1 型糖尿病和 2 型糖尿病，重點關注不同的臨床病程和監測需求，從妊娠相關的血糖控制到強化胰島素治療和慢性病自我護理。因此，產品需求和教育支援必須進行客製化，以應對短暫的妊娠期狀況、終身自體免疫糖尿病管理以及 2 型糖尿病典型的生活方式相關模式。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將連續血糖監測數據與電子健康記錄平台整合
  • 利用近紅外線技術的非侵入式光學葡萄糖感測器的出現
  • 推出一款基於人工智慧的預測分析工具，用於個人化血糖趨勢預測
  • CGM製造商與遠端醫療服務供應商之間的夥伴關係在全球範圍內不斷擴大。
  • 透過遠端患者監護擴展基於訂閱的血糖監測服務
  • 實施可互通的感測器和胰島素幫浦通訊標準以實現自動化
  • 開發適用於兒童和老年人、所需樣本量較小的血糖感測器

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按應用分類的血糖監測市場

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

9. 按最終用戶分類的血糖監測市場

  • 門診治療
  • 診斷實驗室
  • 居家照護
  • 醫院

第10章 依產品類型分類的血糖監測市場

  • 連續血糖監測系統
    • 間歇性掃描系統
    • 即時連續系統
  • 自我監測設備
    • 控制解決方案
    • 血糖值監測儀
    • 穿刺裝置
    • 測試條

第11章 依分銷管道分類的血糖監測市場

  • 醫院診所
  • 線上零售商
  • 藥局

12. 按地區分類的血糖監測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 依組別分類的血糖監測市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國血糖監測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Roche Diagnostics International AG
    • Abbott Laboratories
    • Dexcom, Inc.
    • LifeScan, Inc.
    • Ascensia Diabetes Care Holdings AG
    • Medtronic plc
    • Becton, Dickinson and Company
    • Nova Biomedical Corporation
    • Nipro Corporation
    • Sinocare, Inc.
Product Code: MRR-957C47F90031

The Blood Glucose Monitoring Market is projected to grow by USD 27.23 billion at a CAGR of 8.59% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 14.08 billion
Estimated Year [2025] USD 15.27 billion
Forecast Year [2032] USD 27.23 billion
CAGR (%) 8.59%

A compelling overview of how technological progress, care model evolution, and regulatory forces are reshaping blood glucose monitoring practice and patient outcomes

The management of blood glucose levels sits at the intersection of clinical outcomes, patient autonomy, and technological innovation. Over the past decade, continuous improvements in sensor accuracy, data connectivity, and wearable ergonomics have elevated monitoring from episodic measurement to sustained, insight-driven care. Consequently, clinicians increasingly integrate trend-based information into therapeutic decisions while patients benefit from real-time feedback that supports self-management and adherence. These shifts have implications for product development, reimbursement strategies, and care pathways across primary, ambulatory, and specialized settings.

In parallel, regulatory scrutiny and quality standards have intensified, prompting manufacturers and service providers to prioritize interoperability, data privacy, and clinical validation. Healthcare systems are adapting reimbursement frameworks to recognize remote monitoring and telehealth-enabled interventions, which further incentivizes adoption of advanced monitoring technologies. At the same time, demographic and lifestyle factors continue to drive demand for solutions that accommodate gestational diabetes management, pediatric care, and adult chronic disease control. Taken together, these developments create a more complex but opportunity-rich environment for stakeholders seeking to deliver value through improved glycemic outcomes.

This executive summary synthesizes those dynamics, highlights transformative structural shifts, and outlines actionable recommendations for clinical leaders, product teams, payers, and distribution partners as they navigate the evolving landscape of blood glucose monitoring.

How sensor advancements, digital integration, and decentralized care models are converging to transform blood glucose monitoring and clinical workflows

The landscape of blood glucose monitoring is undergoing transformative shifts driven by technology convergence, evolving care delivery, and changing patient expectations. First, sensor technology has matured to support longer wear times, improved accuracy across glycemic ranges, and reduced calibration requirements. As a result, clinicians can rely on more consistent longitudinal data, enhancing the ability to identify patterns and intervene earlier. In tandem, the expansion of digital health infrastructure-cloud platforms, interoperable electronic health records, and secure patient portals-has enabled seamless transmission of glucose data into clinical workflows, thereby shortening the loop from measurement to clinical action.

Moreover, care delivery models are moving toward decentralized paradigms. Remote monitoring, virtual diabetes education, and community-based programs are reducing dependence on centralized laboratory testing and facilitating earlier intervention in ambulatory and home-care settings. These delivery innovations are complemented by patient-facing improvements: simplified device interfaces, personalized alerts, and gamified adherence tools that increase engagement and retention. Meanwhile, payers and regulators are adapting policies to support remote monitoring and real-world evidence generation, which further accelerates adoption.

Taken together, these shifts create a feedback loop where better data informs better care, and improved care models increase demand for advanced monitoring solutions. Stakeholders that align product development, reimbursement strategy, and clinical integration will be best positioned to capture value and drive sustained improvements in glycemic management.

How 2025 tariff changes reshaped procurement, supply resilience, and pricing strategies across manufacturing and distribution of blood glucose monitoring solutions

Tariff policy and trade dynamics can materially influence supply chains, component sourcing, and pricing strategies for medical devices. In the context of blood glucose monitoring, cumulative tariff changes in 2025 prompted manufacturers and distributors to reassess procurement pathways, diversify supplier bases, and optimize inventory strategies to mitigate cost volatility. Firms responded by accelerating nearshoring and regional sourcing initiatives to reduce exposure to cross-border tariff fluctuations and to enhance supply resilience. Consequently, procurement teams restructured agreements to include alternative suppliers for critical components such as sensors, adhesives, and electronic modules.

Operational adjustments extended beyond sourcing. Logistics teams implemented multi-modal transportation plans and increased buffer stocks at regional distribution centers to maintain continuity of supply. These tactics preserved product availability for hospitals, home care providers, and retail channels while limiting abrupt price adjustments for end users. At the same time, manufacturers intensified negotiations with contract manufacturers and component vendors to share risk and stabilize unit economics.

From a strategic perspective, tariff-driven pressures encouraged stronger collaboration between commercial and regulatory functions to streamline customs clearance and compliance processes. They also highlighted the importance of product design decisions that reduce reliance on tariff-sensitive inputs. Ultimately, organizations that adopted agile sourcing, invested in regional supply nodes, and aligned pricing frameworks with cost pass-through mechanisms navigated the tariff environment more effectively while sustaining service levels across clinical and consumer channels.

Precision segmentation insights that reveal clinical use cases, end-user demands, product families, and distribution pathways to guide targeted strategies and innovation

Segmentation analysis provides clarity on where clinical demand, payer focus, and product innovation converge, enabling targeted strategies across therapeutic and commercial dimensions. Based on Application, the market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes, which underscores varied clinical trajectories and monitoring needs from pregnancy-related glycemic control to intensive insulin management and chronic disease self-care. As a result, product requirements and educational support must be tailored to accommodate transient gestational conditions, lifelong autoimmune diabetes management, and the lifestyle-related patterns typical of Type 2 Diabetes.

Based on End User, the market is studied across Ambulatory Care, Diagnostic Laboratories, Home Care, and Hospitals, indicating that deployment models differ by care intensity and clinical oversight. Ambulatory and home settings prioritize ease of use, connectivity, and patient education, whereas hospitals and diagnostic laboratories emphasize accuracy, calibration standards, and integration with institutional workflows. This split in end-user needs necessitates differentiated go-to-market approaches and service models to address professional training, procurement cycles, and reimbursement complexity.

Based on Product Type, the market is studied across Continuous Glucose Monitoring Systems and Self Monitoring Devices. The Continuous Glucose Monitoring Systems category is further studied across Intermittently Scanned Systems and Real Time Continuous Systems, reflecting divergence between on-demand scanning solutions and always-on data streams that enable alerts and automated insulin delivery. The Self Monitoring Devices category is further studied across Control Solutions, Glucose Meters, Lancing Devices, and Test Strips, which highlights the breadth of accessory and consumable requirements tied to point-of-care testing. Manufacturers should therefore align R&D, pricing, and lifecycle support with the distinct usage patterns and consumable economics of each product family.

Based on Distribution Channel, the market is studied across Hospitals Clinics, Online Retailers, and Pharmacies, illustrating that accessibility, regulatory compliance, and patient purchasing behaviors vary by channel. Hospitals and clinics center on institutional procurement and clinician preference, pharmacies balance retail demand with professional counseling, and online retailers emphasize convenience, subscription models, and direct-to-consumer fulfillment. Understanding these segmentation layers enables more precise channel strategies and tailored customer engagement that reflect clinical, consumer, and institutional buying drivers.

Regional adoption patterns and healthcare system nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape distribution, reimbursement, and product strategies

Regional dynamics influence adoption patterns, reimbursement frameworks, and competitive positioning across different health systems. In the Americas, health systems span diverse payer models and a dense private provider network, prompting rapid uptake of digital monitoring tools where reimbursement aligns with remote care. This region often leads in direct-to-consumer distribution and sees strong participation from integrated delivery networks that incorporate continuous monitoring into chronic care management programs. Consequently, manufacturers emphasize interoperability with major electronic health records, robust patient support services, and payer engagement strategies to facilitate coverage.

In Europe, Middle East & Africa, the regulatory landscape and procurement practices vary significantly across countries, driving heterogeneous adoption timelines. Western European markets tend to prioritize rigorous clinical validation and structured reimbursement pathways, whereas parts of the Middle East and Africa focus on scalability and affordability. As a result, tailored pricing strategies, public-private partnerships, and localized training initiatives are often necessary to expand access while maintaining clinical standards. Regional distributors play a critical role in navigating regulatory approvals and supply logistics.

Across Asia-Pacific, rapid urbanization, growing private healthcare investment, and rising awareness of chronic diseases have accelerated demand for monitoring technologies. Diverse healthcare infrastructures-ranging from advanced tertiary centers to decentralized primary care-require flexible product portfolios and culturally adapted education programs. Manufacturers frequently pursue strategic alliances and localized manufacturing to meet regulatory requirements and competitive pricing pressures. Taken together, these regional characteristics demand differentiated product roadmaps, channel partnerships, and stakeholder engagement to optimize adoption and impact.

Competitive dynamics and strategic imperatives for device makers, platform providers, and service innovators shaping future leadership in blood glucose monitoring

The competitive landscape features established device manufacturers, specialist sensor developers, software platform providers, and an emerging cohort of integrated care solution vendors. Market leaders focus on driving clinical evidence, improving sensor performance, and expanding ecosystem partnerships that link monitoring data to decision support and therapeutic delivery. Strategic priorities for industry players include enhancing data interoperability, securing regulatory approvals for expanded indications, and building patient support services that increase retention and drive lifetime value.

In this environment, new entrants and technology-focused firms differentiate through niche innovations such as adhesive chemistry improvements, non-invasive sensing research, and advanced analytics that translate raw glucose signals into actionable clinical insights. Partnerships between device companies and digital health platforms facilitate the development of value-added services like medication adherence modules and predictive risk modeling. Meanwhile, contract manufacturers and component suppliers play a pivotal role in scaling production and enabling cost efficiencies.

Competitive positioning increasingly depends on the ability to integrate end-to-end offerings that combine hardware, software, and services. Companies that invest in clinical validation, cultivate payer relationships, and demonstrate real-world outcome improvements will be better placed to secure long-term contracts with health systems and payers. Leaders also prioritize sustainability in design and consumable management to address environmental concerns tied to single-use components and electronic waste.

Actionable cross-functional strategies for manufacturers and healthcare partners to enhance product adoption, supply resilience, and payer-aligned value propositions

Industry leaders should adopt a multifaceted approach that aligns product innovation with clinical integration, payer value, and scalable distribution. First, prioritize interoperability and data governance to ensure devices integrate seamlessly into clinician workflows and meet evolving privacy standards. By doing so, manufacturers will reduce friction during procurement and improve clinician adoption rates. Second, develop differentiated value propositions for distinct clinical applications: solutions for gestational diabetes should emphasize ease of use and maternal-fetal safety, while products targeting Type 1 Diabetes must focus on reliability for intensive insulin management and closed-loop therapy compatibility.

Third, strengthen channel strategies by combining institutional partnerships with direct-to-consumer offerings and subscription models that stabilize lifecycle revenues. Manufacturers should also invest in patient education programs and clinician training to enhance outcomes and minimize device abandonment. Fourth, pursue supply chain resilience through supplier diversification, regional sourcing, and modular design choices that lower exposure to trade policy shifts. Finally, collaborate proactively with payers and health systems to generate real-world evidence that demonstrates clinical and economic value, thereby unlocking reimbursement pathways and facilitating broader adoption.

Implementing these recommendations requires cross-functional coordination between R&D, commercial, regulatory, and clinical teams to translate strategic intent into measurable improvements in access, adherence, and outcomes.

A transparent and rigorous research approach combining peer-reviewed evidence, stakeholder interviews, and comparative device analysis to produce actionable insights

This study synthesizes insights from a combination of secondary sources, primary stakeholder interviews, and systematic device and clinical literature reviews to ensure a robust and transparent methodological foundation. Secondary research included peer-reviewed clinical studies, regulatory filings, device labeling, and technology white papers to capture device performance characteristics and safety profiles. Primary interviews were conducted with clinicians, procurement specialists, payers, and industry executives to validate real-world use cases, procurement behavior, and adoption barriers. These discussions informed qualitative themes around patient engagement, care models, and channel dynamics.

Analytical procedures included comparative device feature mapping, end-user need analysis, and supply chain impact assessments to evaluate how product characteristics align with clinical workflows and distribution realities. Throughout the methodology, strict criteria guided the inclusion of evidence, emphasizing clinical validity, regulatory compliance, and reproducibility. Sensitivity checks and cross-validation against multiple information streams were performed to reduce bias and enhance confidence in thematic conclusions.

Finally, the research adhered to ethical guidelines for interview conduct and data handling, with anonymization of participant responses where requested. The approach prioritized actionable insights and transparency in assumptions to support decision-makers seeking to apply findings across product development, commercial strategy, and health system partnerships.

Synthesis of key strategic imperatives that connect technological advances, clinical integration, and resilient commercialization to improve glycemic outcomes

In conclusion, the blood glucose monitoring landscape is characterized by rapid technological progress, evolving care models, and complex supply chain dynamics that together shape adoption and value realization. Continuous sensing and improved data connectivity enable clinicians and patients to move from episodic measurement toward proactive, trend-based management. At the same time, decentralized care delivery and remote monitoring require new approaches to reimbursement, clinician workflow integration, and patient education. These converging forces create opportunities for stakeholders who align product design, channel strategy, and evidence generation with real-world clinical needs.

Tariff and trade developments have underscored the necessity of supply chain agility and regional diversification to maintain product availability and cost stability. Segmentation insights reveal that therapeutic application, end-user setting, product type, and distribution channel each demand tailored offerings and engagement models. Regionally, varied payer environments and healthcare infrastructures necessitate differentiated commercialization strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Ultimately, organizations that integrate clinical validation, payer collaboration, and operational resilience into their strategic planning will be best positioned to deliver improved glycemic outcomes and capture long-term value. The recommendations outlined here provide a pragmatic starting point for executives seeking to prioritize investments and partnerships in the evolving monitoring ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of continuous glucose monitoring data with electronic health records platforms
  • 5.2. Emergence of non-invasive optical glucose sensing devices leveraging near infrared technology
  • 5.3. Adoption of AI-driven predictive analytics tools for personalized glycemic trend forecasting
  • 5.4. Growing partnerships between CGM manufacturers and telehealth service providers worldwide
  • 5.5. Expansion of subscription-based glucose monitoring services with remote patient monitoring
  • 5.6. Implementation of interoperable sensor-to-insulin pump communication standards for automation
  • 5.7. Development of pediatric and geriatric specific glucose sensors with lower sample volume requirements

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Glucose Monitoring Market, by Application

  • 8.1. Gestational Diabetes
  • 8.2. Type 1 Diabetes
  • 8.3. Type 2 Diabetes

9. Blood Glucose Monitoring Market, by End User

  • 9.1. Ambulatory Care
  • 9.2. Diagnostic Laboratories
  • 9.3. Home Care
  • 9.4. Hospitals

10. Blood Glucose Monitoring Market, by Product Type

  • 10.1. Continuous Glucose Monitoring Systems
    • 10.1.1. Intermittently Scanned Systems
    • 10.1.2. Real Time Continuous Systems
  • 10.2. Self Monitoring Devices
    • 10.2.1. Control Solutions
    • 10.2.2. Glucose Meters
    • 10.2.3. Lancing Devices
    • 10.2.4. Test Strips

11. Blood Glucose Monitoring Market, by Distribution Channel

  • 11.1. Hospitals Clinics
  • 11.2. Online Retailers
  • 11.3. Pharmacies

12. Blood Glucose Monitoring Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood Glucose Monitoring Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood Glucose Monitoring Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Roche Diagnostics International AG
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Dexcom, Inc.
    • 15.3.4. LifeScan, Inc.
    • 15.3.5. Ascensia Diabetes Care Holdings AG
    • 15.3.6. Medtronic plc
    • 15.3.7. Becton, Dickinson and Company
    • 15.3.8. Nova Biomedical Corporation
    • 15.3.9. Nipro Corporation
    • 15.3.10. Sinocare, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOOD GLUCOSE MONITORING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOOD GLUCOSE MONITORING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD GLUCOSE MONITORING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 264. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 265. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 266. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 267. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-20